27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our aim was to test the association of vascular risk factor exposure in midlife with progression of MRI markers of brain aging and measures of cognitive decline. 1 key finding →
Design: cohort study Participants: 1,352 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cancer survivors had a lower risk of Alzheimer's disease than those without cancer, and patients with Alzheimer's disease had a lower risk of incident cancer. 5 key findings →
Design: cohort study Participants: 1,278 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We estimated the remaining lifetime risks of developing Alzheimer's disease (AD) and dementia from all causes, based on data from longitudinal population studies. 5 key findings →
Design: longitudinal study Participants: 198 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Diabetes mellitus did not increase the risk of incident AD in the Framingham cohort overall; however, DM may be a risk factor for AD in the absence of other known major AD risk factors. 3 key findings →
Design: cohort study Participants: 2,210 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cross-sectional epidemiological and clinical research suggests that lower cardiac index is associated with abnormal brain aging, including smaller brain volumes, increased white matter hyperintensities, and worse cognitive performances. 4 key findings →
Design: cross-sectional Participants: 184 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Metabolic dysregulation, especially insulin resistance, was associated with lower brain volumes and executive function in a large, relatively healthy, middle-aged, community-based cohort. 3 key findings →
Design: cross-sectional Participants: 2,439 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Stroke increases a subject's risk of dementia as compared with age- and sex-matched controls. 3 key findings →
Design: case-control study Participants: 212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Some prior studies showed lower circulating BDNF in persons with Alzheimer disease (AD) compared with control participants; however, it remains uncertain whether reduced levels precede dementia onset. 5 key findings →
Design: cohort study Participants: 140 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During the 17-year follow-up period, 164 participants developed dementia; 136 of these cases were AD. 5 key findings →
Participants: 164 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In a large community-based sample of middle-aged adults, BI predicted an increased risk of stroke and dementia independent of vascular risk factors. 5 key findings →
Participants: 1,694 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Selective survival of men with a healthier cardiovascular risk profile and hence lower propensity to dementia might partly explain the higher LTR of dementia/AD in women. 1 key finding →
Participants: 7,901 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lower RBC DHA levels are associated with smaller brain volumes and a "vascular" pattern of cognitive impairment even in persons free of clinical dementia. 3 key findings →
Design: cross-sectional Participants: 1,575 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The LTR of stroke in middle-aged adults is 1 in 6 or more, which is equal to or greater than the LTR of AD. 3 key findings →
Participants: 4,897 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Circulating leptin was associated with a reduced incidence of dementia and AD and with cerebral brain volume in asymptomatic older adults. 4 key findings →
Participants: 785 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD. 3 key findings →
Design: cohort study Participants: 159 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The proposed method offers a fully automated procedure, providing an opportunity to develop an inexpensive, broadly accessible, and easy-to-administer screening tool for MCI-to-AD progression prediction, facilitating development of remote assessment. 1 key finding →
Participants: 166 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The sample included dementia-free participants (mean age 40 ± 9 years; 53% women) of the Framingham Heart Study third-generation cohort with cognitive testing of memory, abstract reasoning, visual perception, attention, and executive function (n = 2,126). 4 key findings →
Participants: 2,126 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mid-life stroke risk factors have been related to late-life cognitive impairment. 4 key findings →
Participants: 1,841 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Ninety-nine new cases of dementia (including 71 of Alzheimer disease) occurred during the follow-up. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Systemic inflammation is associated with ischemia and Alzheimer disease (AD). 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four subtypes emerged: (1) dysnomic (n = 153), (2) dysexecutive (n = 102), (3) amnestic (n = 288), and (4) cluster-derived normal (n = 282) who performed within normal limits on cognitive testing. 4 key findings →
Participants: 153 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The "preclinical phase" of detectable lowering of cognitive functioning precedes the appearance of pAD by many years. 2 key findings →
Participants: 1,076 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Greater arterial stiffness and pressure pulsatility are associated with brain aging, MRI vascular insults, and memory deficits typically seen in Alzheimer dementia. 2 key findings →
Participants: 1,587 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The proposed approach offers a fully automated identification of MCI and dementia based on a recorded neuropsychological test, providing an opportunity to develop a remote screening tool that could be adapted easily to any language. 1 key finding →
Participants: 1,084 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This proof-of-concept study demonstrates that automated deep learning-driven processing of audio recordings of neuropsychological testing performed on individuals recruited within a community cohort setting can facilitate dementia screening. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →